Premium
Endocrine and clinical effects of leuprolide in prostatic cancer
Author(s) -
Vance Michael A,
Smith Joseph A
Publication year - 1984
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1984.186
Subject(s) - testosterone (patch) , medicine , leuprorelin , prostate cancer , hormone , luteinizing hormone , endocrine system , vasomotor , androgen , endocrinology , clinical pharmacology , prostate , cancer , oncology , gonadotropin releasing hormone , pharmacology
Twenty‐nine subjects with metastatic carcinoma of the prostate received daily subcutaneous injections of leuprolide, a luteinizing hormone‐releasing hormone analog. After transient gonadotropin and androgen stimulation, leuprolide induced long‐term suppression of serum testosterone and gonadotropins production. In 25 subjects there was objective disease stabilization or tumor regression. Eleven subjects subsequently relapsed (median = 10 mo) after initiation of treatment. Except for vasomotor hot flashes, leuprolide appears to be well tolerated by patients with advanced prostatic cancer. Clinical Pharmacology and Therapeutics (1984) 36, 350–354; doi: 10.1038/clpt.1984.186